More Questions than Answers at Gene Editing Summit
By Chloe Poston,
Genes to Genomes
| 12. 09. 2015
[cites CGS' Marcy Darnovsky]
Last week, the National Academies of Science and Engineering joined forces with the Chinese Academy of Science and the Royal Society of the United Kingdom to host an International Summit on Human Gene Editing in Washington, DC. Top scholars in genetics, bioengineering, ethics, and law debated the merits of human gene editing; however consensus was far from achieved. In fact, the repeated reminders of “unknown unknowns” and references to Brave New World left participants wondering how such disparate opinions could be formed into a single set of guidelines from the summit organizing committee.
The final statement from the organizing committee, released at the conclusion of the summit, signified that this gathering would not be the place where final decisions were made. Instead, the committee used the three days of insightful perspectives to develop a framework for how information should be collected. The point of the summit was not to answer the looming questions surrounding human gene editing; rather, it was to determine what questions to ask—and of whom—in order to begin developing recommendations on how to move forward with this technology.
The mix of...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...